These Analysts Cut Their Forecasts On Moderna After Q3 Results
Portfolio Pulse from Lisa Levin
Moderna Inc (MRNA) reported a Q3 loss of $(9.53), down from EPS income of $2.53, missing analysts' estimate of $(1.93). Sales reached $1.8 billion, beating the consensus of $1.4 billion but down from $3.4 billion a year ago. HSBC and Goldman Sachs lowered their price targets on Moderna following the earnings announcement.
November 03, 2023 | 4:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna's Q3 results missed estimates, leading to a decrease in price targets by HSBC and Goldman Sachs. Despite beating sales consensus, the YoY decrease may impact investor sentiment.
Moderna's Q3 results were below expectations, which led to a decrease in price targets by HSBC and Goldman Sachs. This could negatively impact the stock price in the short term. Additionally, despite beating sales consensus, the YoY decrease may negatively impact investor sentiment and further pressure the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100